Wedbush Securities

Valkyrie Investments is a specialized alternative asset management firm.

Headquartered in Los Angeles with a satellite offices in Dallas and Chicago, Valkyrie assists clients on and between coasts. Valkyrie is a multi-asset management company providing a wide range of investment management services to clients as trusted fiduciary advisors. We create and manage bespoke portfolios, including safe exposure to digital assets and other frontier investments. Whether you’re an endowment, entrepreneur, family office, or individual, we will not only protect your wealth but we’ll also help it thrive in the world. At Valkyrie, our mission is to invest responsibly to enable economic prosperity, technological innovation, and social progress.

Dianthus Therapeutics is a biotech company operating in stealth mode. It was founded in 2019 and is based in Waltham, Massachusetts.

Shoreline Biosciences, Inc. is a biotechnology company based in La Jolla, California, founded in 2020. The company specializes in developing cell-based immunotherapies aimed at treating seriously ill patients. Shoreline utilizes a proprietary technology platform that focuses on induced pluripotent stem cell (iPSC) differentiation and the genetic programming of the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, thereby improving their anti-cancer activity. In addition to NK cells, Shoreline is also advancing the development of iPSC-derived macrophages for oncology and disease-modifying therapies. The company's innovative solutions aim to provide healthcare professionals with effective and cost-efficient treatment options for patients facing serious health challenges.

BioTheryX, Inc. is a biopharmaceutical company based in Chappaqua, New York, that specializes in the development of therapies for hematological malignancies and other diseases. The company focuses on restoring protein homeostasis through innovative approaches such as Protein Homeostatic Modulators, which are small molecular glue cereblon binders with significant therapeutic potential. Additionally, BioTheryX is advancing targeted protein degradation technologies, including PROTACs, which utilize dual ligands to facilitate the degradation of specific proteins. The company also offers BTX-A51, an oral small molecule that acts as a multi-kinase inhibitor to target leukemic stem cells and suppress key oncogenic gene transcription. Founded in 2007, BioTheryX aims to expedite the delivery of effective therapies to patients with unmet medical needs by leveraging enhanced biology-driven models and clinically proven translational approaches.

ETFMG is a provider of exchange-traded funds (ETFs), with a vision of developing innovative thematic ETFs that provide investors unique exposure to new markets. Today, the ETFMG fund line up provides access to a diverse collection of global themes and is comprised of 75% first to market products. We turn portfolio management strategies into successful ETFs by partnering with market segment experts to bring long-term growth opportunities to investors. ETFMG funds are proof as to the power of the ETF wrapper and that thematic products can have a place in investors’ portfolios.

Alan Kluis has been a commodity advisor and broker since 1976. He is president and managing partner of Kluis Commodities and Kluis Publishing in Wayzata, Minnesota. Alan is an introducing broker with R.J.O'Brien. Alan is also a writer. He writes a column, Your Profit, which appears in every issue of Successful Farming magazine. Alan has published two books on commodities trading. Alan is commonly quoted in major publications including the Wall Street Journal, and is a featured speaker at commodity conferences nationwide. He is a frequent market analyst for the Linder Farm Radio News Network. Alan is the author of the weekly commodity advisory newsletter, The Al Kluis Report and works with a team to send out a daily email report to 3,000 subscribers. Alan, a Minnesota farmboy, was awarded his degree in Ag Economics from the University of Minnesota in 1974, after which he was executive director of the Minnesota Soybean Association before entering the markets full-time. Alan's family still farms in southwest Minnesota and Al enjoys helping with fieldwork when the markets allow.

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company based in Calgary, Canada, focused on the discovery and development of innovative treatments for cancer. Its primary product, pelareorep, is an immuno-oncology therapeutic derived from reovirus, designed to target solid tumors and hematological malignancies by enhancing the immune system's ability to combat cancer. The company has established collaboration agreements with prominent partners, including Merck KGaA and Pfizer, to explore combinations of pelareorep with other treatments, such as paclitaxel and avelumab, particularly for hormone-receptor positive, HER2-negative metastatic breast cancer. Oncolytics Biotech is also advancing additional projects in its pipeline, including treatments aimed at gastrointestinal cancers and breast cancer. Founded in 1998, the company continues to strive for breakthroughs in cancer therapeutics.

Pacific Growth Equities is a research driven investment bank that specializes in technology based emerging growth companies. They are dedicated to providing high quality research for institutional investors and superior execution for their corporate clients. The idea of working harder to help institutions understand and invest in complicated growth stocks is not new. Fast moving growth companies and investors in those companies have long relied on a better quality of service from focused investment banks like Pacific Growth Equities. Consolidation in the financial services industry combined with a single minded focus on investment banking revenue among those firms that remain have left investors and companies with an ever dwindling pool of independent, reliable advisors. They offer a full range of investment banking and brokerage services including Public Equity offerings, Private Equity offerings, and Mergers & Acquisitions. Their focus is on those life sciences, technology, healthcare and consumer growth companies where their brand of high value in-depth research makes a difference. Their Sales & Trading team is broad and deep, with on average 15 years of experience working with growth stocks. They enjoy mutually respectful relationships with the top institutional buyers of emerging growth stocks both in the US and abroad. Perhaps most important of all, their clients have immediate access to senior professionals in every area of the firm. They're not only large enough to serve all your investment banking needs, they haven't forgotten that "hands on" management from their top people is critical to successful completion of your transaction. And since they're independent and employee-owned, you're always dealing with someone who owns a piece of the business. Pacific Growth Equities is an entrepreneurial company focused on getting the job done. They have brought together years of experience at old-line investment banks, and eliminated the politics and slow-moving, top-heavy corporate mentality. Their corporate culture was forged in the entrepreneurial climate of the information age, and they often find that their business style is more closely attuned to their entrepreneurial clients than their co-managers. Innovation is part of doing business at Pacific Growth Equities. They have a history of being very creative and coming up with "outside the box" solutions to meet the needs of both their institutional and investment banking clients. They believe that the best ideas have frequently not been tried before.